JP2000509276A - インターフェロンアルファ/ベータ受容体に対する抗体 - Google Patents
インターフェロンアルファ/ベータ受容体に対する抗体Info
- Publication number
- JP2000509276A JP2000509276A JP9538378A JP53837897A JP2000509276A JP 2000509276 A JP2000509276 A JP 2000509276A JP 9538378 A JP9538378 A JP 9538378A JP 53837897 A JP53837897 A JP 53837897A JP 2000509276 A JP2000509276 A JP 2000509276A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ifn
- antibodies
- ifnab
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. IFN-α/β受容体またはその可溶性形態のIFNAB-BPIおよびI FNAB-BPIIと結合し、IFN-αの生物学的活性をブロックする抗体。 2. 抗体がIFN-αおよびIFN-βの生物学的活性をブロックする、請求の 範囲第1項記載の抗体。 3. 抗体がIFN-αの生物学的活性を選択的にブロックする、請求の範囲第1 項記載の抗体。 4. 抗体がモノクローナル抗体である、請求の範囲第1項記載の抗体。 5. 抗体がポリクローナル抗体である、請求の範囲第1項記載の抗体。 6. 抗体がキメラ抗体である、請求の範囲第1項記載の抗体。 7. 抗体がヒト化されている、請求の範囲第1項記載の抗体。 8. 抗体がモノクローナル抗体である、請求の範囲第3項記載の抗体。 9. 抗体がポリクローナル抗体である、請求の範囲第3項記載の抗体。 10. 抗体がキメラ抗体である、請求の範囲第3項記載の抗体。 11. 抗体がヒト化されている、請求の範囲第3項記載の抗体。 12. 請求の範囲第1項記載の抗体をコードするDNAセグメントからなるDN A分子。 13. DNAが組換えDNA分子である、請求の範囲第12 項記載のDNA分子。 14. 前記抗体をコードするDNAセグメントが、転写調節シグナルおよび翻訳 調節シグナルに作動可能に連結されている、請求の範囲第12項記載のDNA分子 。 15. 請求の範囲第13項記載の組換えDNA分子からなる発現ベクター。 16. 請求の範囲第15項記載の発現ベクターを担持し、抗体を発現できる宿主細 胞。 17. 請求の範囲第16項記載の宿主細胞を培養し抗体を発現させることからなる 抗体の製造法。 18. 請求の範囲第1項記載の抗体と薬学的に許容し得る担体からなる、IFN -αの生物学的活性をモジュレートするためまたはブロッキングするための医薬 組成物。 19. 有効量の請求の範囲第18項記載の医薬組成物をIFN-αの生物学的活性 をモジュレートするまたはブロックする必要がある対象に投与する工程からなる 、前記活性をモジュレートするまたはブロックする方法。 20. NUR 2 117.7と呼称し、受託番号I-1698として1996年4月23日付でパ スツール・インスティチュートに寄託された、請求の範囲第1項記載の抗体を発 現するハイブリドーマ。 21. NUR 2 234.14と呼称し、受託番号I-1699として1996年4月23日付でパ スツール・インスティチュートに寄託された、請求の範囲第1項記載の抗体を発 現するハイブリドーマ。 22. モノクローナル抗体46.10およびモノクローナル抗体117.7のいずれかの第 1のコーティング、およびモノクローナル抗体234.14の第2のコーティングを備 え る市販のマイクロタイタープレートからなるIFNAB-BPIおよび/または IFNAB/BPIIのELISA試験具。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL118096 | 1996-05-01 | ||
IL11809696A IL118096A0 (en) | 1996-05-01 | 1996-05-01 | Antibodies against interferon alpha/beta receptor |
PCT/IL1997/000138 WO1997041229A1 (en) | 1996-05-01 | 1997-04-29 | Antibodies against interferon alpha/beta receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000509276A true JP2000509276A (ja) | 2000-07-25 |
JP4308322B2 JP4308322B2 (ja) | 2009-08-05 |
Family
ID=11068814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53837897A Expired - Lifetime JP4308322B2 (ja) | 1996-05-01 | 1997-04-29 | インターフェロンアルファ/ベータ受容体に対する抗体 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6136309A (ja) |
EP (2) | EP1739177A1 (ja) |
JP (1) | JP4308322B2 (ja) |
KR (2) | KR20000064953A (ja) |
CN (1) | CN1198929C (ja) |
AT (1) | ATE342981T1 (ja) |
AU (1) | AU719995B2 (ja) |
BR (1) | BR9709202A (ja) |
CA (1) | CA2253239C (ja) |
DE (1) | DE69736835T2 (ja) |
DK (1) | DK0927252T3 (ja) |
EA (1) | EA002543B1 (ja) |
ES (1) | ES2274542T3 (ja) |
HK (1) | HK1019339A1 (ja) |
IL (2) | IL118096A0 (ja) |
NO (1) | NO324206B1 (ja) |
PT (1) | PT927252E (ja) |
UA (1) | UA76396C2 (ja) |
WO (1) | WO1997041229A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009132736A (ja) * | 2001-01-09 | 2009-06-18 | Baylor Research Inst | 対象における自己免疫疾患の治療法及びinvitro診断アッセイ |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US6713609B1 (en) | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
US6376067B1 (en) * | 1998-12-21 | 2002-04-23 | Mitsubishi Polyester Film, Llc | Silicone coated film with back side slip control coating and method of controlling slip of such film |
RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
AU2007202840B2 (en) * | 2001-01-09 | 2011-07-28 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
UA76638C2 (en) * | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
EP1631312B1 (en) * | 2003-04-23 | 2008-09-10 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
AU2007203559B2 (en) * | 2003-04-23 | 2010-09-02 | E. R. Squibb & Sons, L.L.C. | Compositions and methods for the therapy of inflammatory bowel disease |
NZ547157A (en) | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
DK2662390T3 (da) | 2004-06-21 | 2017-11-06 | Squibb & Sons Llc | Interferon alpha receptor 1-antistoffer og anvendelse heraf |
BRPI0607490A2 (pt) | 2005-02-10 | 2009-09-08 | Baylor Res Inst | anticorpos monoclonais antiinterferon alfa e métodos para uso |
US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
CN101243105A (zh) * | 2005-06-22 | 2008-08-13 | 健泰科生物技术公司 | 用于靶向ifnar2的方法和组合物 |
CA2722622C (en) * | 2008-05-07 | 2018-01-02 | Novo Nordisk A/S | Humanized antibodies against human interferon-alpha |
PE20130398A1 (es) | 2010-07-15 | 2013-04-10 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo |
MX2013000542A (es) | 2010-07-15 | 2013-06-28 | Oleg Iliich Epshtein | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. |
WO2018010140A1 (zh) * | 2016-07-14 | 2018-01-18 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
CN115558027B (zh) * | 2022-12-05 | 2023-02-28 | 北京万泰生物药业股份有限公司 | 一种核酸酶的单克隆抗体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
IL108584A (en) * | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of the interferon-binding protein ALPHA / BETA |
IL106591A (en) * | 1992-09-03 | 2008-03-20 | Yeda Res & Dev | Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it |
CA2171955A1 (en) * | 1993-09-17 | 1995-03-23 | Michael G. Tovey | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
-
1996
- 1996-05-01 IL IL11809696A patent/IL118096A0/xx unknown
-
1997
- 1997-04-29 CA CA2253239A patent/CA2253239C/en not_active Expired - Lifetime
- 1997-04-29 PT PT97919622T patent/PT927252E/pt unknown
- 1997-04-29 IL IL126835A patent/IL126835A/en not_active IP Right Cessation
- 1997-04-29 AU AU24027/97A patent/AU719995B2/en not_active Expired
- 1997-04-29 EP EP06014510A patent/EP1739177A1/en not_active Withdrawn
- 1997-04-29 KR KR1019980708393A patent/KR20000064953A/ko active Search and Examination
- 1997-04-29 DE DE69736835T patent/DE69736835T2/de not_active Expired - Lifetime
- 1997-04-29 WO PCT/IL1997/000138 patent/WO1997041229A1/en active IP Right Grant
- 1997-04-29 CN CNB971951861A patent/CN1198929C/zh not_active Expired - Lifetime
- 1997-04-29 ES ES97919622T patent/ES2274542T3/es not_active Expired - Lifetime
- 1997-04-29 AT AT97919622T patent/ATE342981T1/de active
- 1997-04-29 DK DK97919622T patent/DK0927252T3/da active
- 1997-04-29 EA EA199800968A patent/EA002543B1/ru not_active IP Right Cessation
- 1997-04-29 EP EP97919622A patent/EP0927252B1/en not_active Expired - Lifetime
- 1997-04-29 UA UA98116315A patent/UA76396C2/uk unknown
- 1997-04-29 BR BR9709202A patent/BR9709202A/pt active Search and Examination
- 1997-04-29 JP JP53837897A patent/JP4308322B2/ja not_active Expired - Lifetime
- 1997-04-29 KR KR1020047011388A patent/KR100581798B1/ko not_active IP Right Cessation
-
1998
- 1998-04-29 US US09/171,979 patent/US6136309A/en not_active Expired - Lifetime
- 1998-10-29 NO NO19985050A patent/NO324206B1/no not_active IP Right Cessation
-
1999
- 1999-09-30 HK HK99104252A patent/HK1019339A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009132736A (ja) * | 2001-01-09 | 2009-06-18 | Baylor Research Inst | 対象における自己免疫疾患の治療法及びinvitro診断アッセイ |
Also Published As
Publication number | Publication date |
---|---|
JP4308322B2 (ja) | 2009-08-05 |
AU719995B2 (en) | 2000-05-18 |
DE69736835T2 (de) | 2007-11-22 |
CA2253239C (en) | 2010-08-10 |
KR100581798B1 (ko) | 2006-05-25 |
ATE342981T1 (de) | 2006-11-15 |
UA76396C2 (en) | 2006-08-15 |
DE69736835D1 (de) | 2006-11-30 |
CN1198929C (zh) | 2005-04-27 |
IL126835A (en) | 2007-07-24 |
EA002543B1 (ru) | 2002-06-27 |
NO324206B1 (no) | 2007-09-10 |
EP1739177A1 (en) | 2007-01-03 |
ES2274542T3 (es) | 2007-05-16 |
PT927252E (pt) | 2007-01-31 |
CA2253239A1 (en) | 1997-11-06 |
US6136309A (en) | 2000-10-24 |
KR20000064953A (ko) | 2000-11-06 |
IL118096A0 (en) | 1996-09-12 |
DK0927252T3 (da) | 2007-02-05 |
EA199800968A1 (ru) | 1999-04-29 |
WO1997041229A1 (en) | 1997-11-06 |
NO985050L (no) | 1998-12-29 |
HK1019339A1 (en) | 2000-02-03 |
EP0927252A1 (en) | 1999-07-07 |
CN1220699A (zh) | 1999-06-23 |
KR20040075105A (ko) | 2004-08-26 |
EP0927252B1 (en) | 2006-10-18 |
AU2402797A (en) | 1997-11-19 |
NO985050D0 (no) | 1998-10-29 |
BR9709202A (pt) | 1999-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4308322B2 (ja) | インターフェロンアルファ/ベータ受容体に対する抗体 | |
KR100687388B1 (ko) | 인터루킨-18 결합 단백질, 이들의 제조방법 및 용도 | |
US5919453A (en) | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon | |
US20040161858A1 (en) | TNF binding ligands and antibodies | |
US7696154B2 (en) | Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins | |
EP1283217B1 (en) | Antibodies against the IL-8 receptor, and their therapeutic uses | |
US6458932B1 (en) | Interferon-α/β binding protein, its preparation and use | |
JP2005200422A (ja) | インターフェロンα/β結合タンパク質およびその製造法 | |
JP3104187B2 (ja) | インターフエロン―ガンマ結合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040414 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070502 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090414 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090501 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130515 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130515 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |